Latest News about RHHBY
Recent news which mentions RHHBY
Here's Why Everyone's Talking About AstraZeneca Right Now
September 21, 2021
From Motley Fool
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
September 20, 2021
From Benzinga
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
September 18, 2021
From Motley Fool
Why Adaptimmune Therapeutics Was Sinking This Week
September 17, 2021
From Motley Fool
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
From Benzinga
Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know
September 15, 2021
From Benzinga
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
September 14, 2021
From Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
September 14, 2021
From Benzinga
These OTCQX & OTCQB Securities Had the Most Trading Activity in August
September 13, 2021
From Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
September 12, 2021
From Benzinga
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
September 10, 2021
From InvestorPlace
Why MacroGenics Soared Nearly 9% Higher Today
September 09, 2021
From Motley Fool
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
From Benzinga
Roche Beefs Up PCR-Test Portfolio With TIB Molbiol Acquisition
September 09, 2021
From Benzinga
2 Stocks I Bought Last Week
September 08, 2021
From Motley Fool
MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis
September 08, 2021
From Benzinga
7 Meme Stocks You Should Keep a Close Eye on for Real Potential
September 07, 2021
Tags
NYSE:GM,NASDAQ:AMZN,NYSE:SAND,NASDAQ:HOOD,NYSE:TSM,NYSE:QUAD,NASDAQ:FORD,NYSE:VZ,OTCMKTS:RHHBY
FORD
SAND
From InvestorPlace
Why Adaptimmune Therapeutics Stock Is Bolting Higher Today
September 07, 2021
From Motley Fool
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech
September 07, 2021
From Benzinga
Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy
September 07, 2021
From Benzinga
Is Exelixis Stock a Buy?
September 02, 2021
From Motley Fool
COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?
August 31, 2021
From Motley Fool
From Benzinga
From Benzinga
From Benzinga
Which Biotech Stock Will Shock the Market in 2022?
August 27, 2021
From Motley Fool
Shape Therapeutics, Roche Form $3B RNA Editing Collaboration
August 24, 2021
From Benzinga
Why Shares of Global Blood Therapeutics Are Soaring Today
August 23, 2021
From Motley Fool
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail
August 20, 2021
From Benzinga
Could Biogen Acquire Axsome Therapeutics?
August 20, 2021
From Motley Fool